Schizophrenia Research
Volume 56, Issue 1 , Pages 37-46 , 1 July 2002

Personal evaluation of transitions in treatment (PETiT):a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia

  • Lakshmi N.P Voruganti

      Affiliations

    • Institute of Medical Science, University of Toronto, Toronto, Canada
    • Department of Psychiatry, University of Western Ontario, London, Ontario, Canada
    • Corresponding Author InformationCorresponding author. Tel.: +1-519-455-5110; fax: +1-519-858-4607
    • ,
  • A.George Awad

      Affiliations

    • Institute of Medical Science, University of Toronto, Toronto, Canada

Received 14 September 2000 ,Revised 15 December 2000 ,Accepted 18 December 2000.

References 

  1. Arbuckle JL. Amos User's Guide. Chicago: Smallwaters; 1995;
  2. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin. 1993;19:609–618
  3. Awad AG, Voruganti L, Heslegrave R. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Quality of Life Research. 1997;6:21–26
  4. Awad, A.G., Mastey, V., McDonald, D., 1999. The link between drug attitudes, compliance and behaviour. Poster presented at the Annual Meeting of the American Psychiatric Association, Washington, DC.
  5. Barry MM, Zissi A. Quality of life as an outcome measure in evaluating mental health services: a review of the empirical evidence. Social Psychiatry & Psychiatric Epidemiology. 1997;32:38–47
  6. Blyler CR, Fenton WS. Satisfaction with treatment outcome and noncompliance in schizophrenia. Schizophrenia Research. 1997;24(1,2):205
  7. Cattell RB. The Scree test for the number of factors. Multivariate Behavioral Research. 1966;1:245–276
  8. Collins E, Hogan T, Desai H. Measurement of therapeutic response in schizophrenia: a critical survey. Schizophrenia Research. 1991;5:249–253
  9. Diamond R. Drugs and quality of life: the patient's point of view. Journal of Clinical Psychiatry. 1985;46(5):29–35
  10. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The Global Assessment Scale: a procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry. 1976;33:766–771
  11. Expert consensus guidelines on schizophrenia treatment. 1999. Journal of Clinical Psychiatry (Supple. 9), 1–88.
  12. Hamilton S, Revicki DA, Edgell ET, Genduso LA, Tollefson G. Clinical and economic outcomes of olanzepine compared with haloperidol for schizophrenia. Results from a randomized clinical trial. Pharmacoeconomics. 1999;15(5):469–480
  13. Heinrichs D, Hanlon E, Carpenter W. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin;. 1984;10:388–398
  14. Hogan TP, Awad AG, Eastwood R. A self report scale predictive of drug compliance in schizophrenics: reliability and discriminant validity. Psychological Medicine. 1983;13:177–183
  15. Kaiser HF. The varimax criterion for analytic rotation in factor analysis. Psychometrika. 1958;34:187–200
  16. Kay S, Fiszbein A, Opler L. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin. 1987;13:261
  17. Kerlinger FN. In: Foundations of Behavioural Research. New York: Holt, Rinehart and Winston Inc; 1973;p. 582–600
  18. Knapp M. The health economics of schizophrenia treatment. In:  Moscarelli M,  Rupp A,  Sartorius N editor. Handbook of Mental Health Economics and Health Policy. vol. 1:John Wiley & Sons; 1996;p. 385–398
  19. Krueger RA. Focus Groups. A Practical Guide for Applied Research. London: Sage Publications; 1994;
  20. Lehman A. Evaluating outcomes of treatments for persons with psychotic disorders. Journal of Clinical Psychiatry. 1996;57(Suppl. 11):61–67
  21. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry. 1990;41(8):892–897
  22. Meltzer H. Outcome in schizophrenia: beyond symptom reduction. Journal of Clinical Psychiatry. 1999;60(Suppl. 3):3–7
  23. Morse J. Approaches to qualitative-quantitative methodological triangulation. Nursing Research. 1991;40:120–123
  24. Rush AJ, Pincus HA, First MB, et al.  Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000;
  25. Spilker B. (Ed.), 1996. Adopting higher standards for quality of life trials. In: Quality of Life and Pharmacoeconomics in Clinical Trials. Lippincott-Raven, Philadelphia, pp. 57–58.
  26. Streiner D, Norman G. Health Measurement Scales: A Practical Guide to their Development and Use. Oxford University Press. 1993;86
  27. Van Putten T, May PRA, Marder SR, Wittmann L. Subjective response to antipsychotic drugs. Archives of General Psychiatry. 1981;38:187–190
  28. Voruganti L, Heslegrave R, Awad AG. Quality of life measurement during antipsychotic drug therapy of schizophrenia. Journal of Psychiatry & Neuroscience. 1997;22:267–274
  29. Voruganti L, Cortese L, Ouyewumi L, Cernovsky Z, Zirul S, Awad AG. Comparative evaluation of conventional and new antipsychotic drugs with reference to their subjective tolerability, side effect profile and impact on quality of life. Schizophrenia Research. 2000;43:135–145

PII: S0920-9964(01)00161-X

doi: 10.1016/S0920-9964(01)00161-X

Schizophrenia Research
Volume 56, Issue 1 , Pages 37-46 , 1 July 2002

Article Tools

* Image Usage & Resolution